Literature DB >> 6108205

Flunitrazepam: a review of its pharmacological properties and therapeutic use.

M A Mattila, H M Larni.   

Abstract

Flunitrazepam is a benzodiazepine derivative whose hypnotic effect predominates over the sedative, anxiolytic, muscle-relaxing and anticonvulsant effects characteristic of benzodiazepines. Thus, it is used as a night-time hypnotic and in anaesthesiology: due to the pronounced hypnotic effect it is not appropriate as a daytime sedative. As a hypnotic for insomnia its effect is usually characterised by a very fast onset of action and quiet sleep without interruptions. On the morning after a hypnotic dose some residual psychomotor impairment does occur, which is comparable to that with usual doses of nitrazepam or flurazepam, but clinically apparent 'hangover' occurs infrequently. There is no pronounced cumulative effect with chronic use. In anaesthesiology it has proven to be useful as a hypnotic on the night before operation, as an oral, intramuscular or intravenous premedication, in induction and as a supplement to other anaesthetics. Its sedative and amnesic properties can also be beneficial in intensive care patients. Much of the usefulness of flunitrazepam in anaesthesia relates to its synergistic effect with other anaesthetics, to its effective amnesic action and its acceptable effects on circulation and respiration. Possible drawbacks include a somewhat unusual course of induction (when used for this purpose) and an often prolonged recovery. Although the safe dosage range is wide with flunitrazepam, its effective application both as a hypnotic for insomnia and in anaesthesiology is dependent upon use of the optimal dosage, and adequate knowledge of its pharmacokinetic properties.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108205     DOI: 10.2165/00003495-198020050-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  57 in total

1.  Synaptic pharmacology of barbiturates and benzodiazepines.

Authors:  W E Haefely
Journal:  Agents Actions       Date:  1977-09

2.  Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial.

Authors:  I Freuchen; J Ostergaard; J B Kühl; B O Mikkelsen
Journal:  Acta Anaesthesiol Scand       Date:  1976       Impact factor: 2.105

3.  Comparison of diazepam and flunitrazepam for sedation during local anaesthesia for bronchoscopy.

Authors:  K Korttila; L Saarnivaara; J Tarkkanen; J J Himberg; M Hytönen
Journal:  Br J Anaesth       Date:  1978-03       Impact factor: 9.166

4.  Polyethylene glycol as a solvent for diazepam: bioavailability and clinical effects after intramuscular administration, comparison of oral, intramuscular and rectal administration, and precipitation from intravenous solutions.

Authors:  K Korttila; A Sothman; P Andersson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-07

5.  Double-blind study of flunitrazepam (Ro 5-4200) and Mandrax.

Authors:  E Wickstrom
Journal:  Anaesthesist       Date:  1974-02       Impact factor: 1.041

6.  Hemodynamic studies of flunitrazepam or RO 05-4200 injection in man.

Authors:  G Rolly; P Lamote; P Cosaert
Journal:  Acta Anaesthesiol Belg       Date:  1974

7.  Effect of age on amnesia and sedation induced by flunitrazepam during local anaesthesia for bronchoscopy.

Authors:  K Korttila; L Saarnivaara; J Tarkkanen; J J Himberg; M Hytönen
Journal:  Br J Anaesth       Date:  1978-12       Impact factor: 9.166

8.  [The sedative and amnesic effects of flunitrazepam during regional anaesthesia (author's transl)].

Authors:  W Tolksdorf; J Berlin; U Bethke; J P Striebel; K T Westphal; H Lutz
Journal:  Prakt Anaesth       Date:  1979-02

9.  Relative amnesic actions of diazepam, flunitrazepam and lorazepam in man.

Authors:  K A George; J W Dundee
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

Review 10.  Receptors for the age of anxiety: pharmacology of the benzodiazepines.

Authors:  J F Tallman; S M Paul; P Skolnick; D W Gallager
Journal:  Science       Date:  1980-01-18       Impact factor: 47.728

View more
  23 in total

1.  Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam.

Authors:  A Grahnén; P Wennerlund; B Dahlström; S A Eckernäs
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Psychotropic drug-associated electrocardiographic presentation of diffuse J-waves in hypothermia: case report and literature review.

Authors:  Hajime Kataoka; Hirofumi Kajiwara; Eiji Yano
Journal:  Heart Vessels       Date:  2015-02-11       Impact factor: 2.037

3.  A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers.

Authors:  M Farré; M T Terán; J Camí
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

4.  Hypnotics and anxiolytics.

Authors:  N Hockings; B R Ballinger
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-18

5.  Flunitrazepam protects mice against lidocaine and bupivacaine-induced convulsions.

Authors:  E Vatashsky; H B Aronson
Journal:  Can Anaesth Soc J       Date:  1983-01

6.  Flunitrazepam in outpatient dentistry.

Authors:  P A Foreman
Journal:  Anesth Prog       Date:  1982 Mar-Apr

7.  Flunitrazepam versus diazepam for endoscopies.

Authors:  E Vatashsky; Y Haskel; H B Aronson
Journal:  J R Soc Med       Date:  1982-08       Impact factor: 5.344

8.  Residual effects of repeated doses of 0.5 and 1 mg flunitrazepam.

Authors:  M Lader; A Melhuish; P Harris
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Amnesic effects and subjective ratings during repeated dosing of flunitrazepam to healthy volunteers.

Authors:  J Ingum; K M Beylich; J Mørland
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method.

Authors:  E Fabre; S Chevret; J F Piechaud; E Rey; F Vauzelle-Kervoedan; P D'Athis; G Olive; G Pons
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.